Epigenetic marks including histone modifications and DNA methylation are associated with the regulation of gene expression and activity. In addition, an increasing number of non-coding RNAs with regulatory activity on gene expression have been identified. Alongside, technological advancements allow for the analysis of these mechanisms with high resolution up to the single-cell level. For instance, the assay for transposase-accessible chromatin using sequencing (ATAC-seq) simultaneously probes for chromatin accessibility and nucleosome positioning. Thus, it provides information on two levels of epigenetic regulation. Development and differentiation of T cells into functional subset cells including memory T cells are dynamic processes driven by environmental signals. Here, we briefly review the current knowledge of how epigenetic regulation contributes to subset specification, differentiation and memory development in T cells. Specifically, we focus on epigenetic mechanisms differentially active in the two distinct T cell populations expressing ab or cd T cell receptors. We also discuss examples of epigenetic alterations of T cells in autoimmune diseases. DNA methylation and histone acetylation are subject to modification by several classes of 'epigenetic modifiers', some of which are in clinical use or in preclinical development. Therefore, we address the impact of some epigenetic modifiers on T-cell activation and differentiation, and discuss possible synergies with T cellbased immunotherapeutic strategies.
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Epigenetic mechanisms and technological advancements
Epigenetic mechanisms are associated with gene expression and ultimately protein expression. The chromatin and RNA molecules are key players in this complex network. Core structures of the chromatin are DNA-protein complexes called nucleosomes, which consist of 147 bp of DNA and a heterodimer of histones H1, H2, H3 and H4. The nucleosomes can act as a barrier to DNA-binding proteins, but processes such as transcription and replication require free access to the DNA template. The nucleosome remodelling involves changes in DNA-protein interactions by disrupting, disassembling or moving nucleosomes and thus allowing DNA to get accessible for further processes. Consequently, chromatin accessibility and nucleosome remodelling are highly important for gene expression [1] . The chromatin is substantially modulated by epigenetic modifications, notably DNA and histone modifications.
DNA modifications include the most widely studied 5-methylcytosine (5mC) and the relatively newly discovered 5-hydroxymethylation (5hmC), 5-formylcytosine (5fC) and 5-carboxycytosine (5caC) [2, 3] . BeadChip arrays are commonly used for analysis of DNA methylation. Compared to sequencing methods like whole-genome bisulphite sequencing (WGBS) or reduced-representation bisulphite sequencing (RRBS), which need extensive bioinformatics expertise, array-based genome-wide studies are easy to handle but cover only a fraction of all CpG sites. Importantly, a substantial proportion of differentially methylated regions (DMRs) are located outside the CpG islands in the 'open sea', yet are important for regulation of gene expression. Gene expression is further regulated at the epigenetic level through histone modifications including acetylation and (tri)methylation. Alternatively, regulation of gene expression targeting non-histone proteins can be mediated by competitive non-histone-like modifications in a non-epigenetic process [4] . An interrelated role of both epigenetic and non-epigenetic processes in the regulation of inflammatory genes is addressed through the development of synthetic compounds targeting proteins that recognize post-translationally modified histones [5] . However, this review will focus on the epigenetic processes.
Once a particular gene is expressed, RNA transcripts are produced. At this stage, RNA undergoes several ways of controlled regulation. Together with protein-coding transcripts (mRNA), non-coding RNA (ncRNA) with a size between 20 and 200 nucleotides, for example microRNA/ miRNA, small nucleolar RNA/snoRNA, small nuclear RNA/snRNA, piwi-interacting RNA/piRNA, transfer RNA/tRNA, and long non-coding RNA with more than 200 nucleotides, for example antisense ncRNA, enhancer ncRNA/eRNA, intergenic RNA/lincRNA, pseudogene RNA, 3 0 UTR ncRNA, play important roles in the overall regulation of RNA expression [6, 7] . Last but not least, the successfully translated protein undergoes various posttranslational modifications such as palmitoylation, phosphorylation and ADP-ribosylation with significance for cellular differentiation and cell signalling [8] .
Recently, innovative technologies became available to study transcription and epigenetic regulation like histone modifications and chromatin accessibility on a genomewide level. High-throughput RNA-based sequencing (RNA-seq) is used for global transcriptome analysis up to the single-cell level [9] and can be also applied to noncoding RNAs [10, 11] . Histones can be modified by methylation or acetylation at specific amino acids which can be studied by chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) [12] . Such active epigenetic 'marks' are for instance the trimethylation of histone H3 at Lysine 4 (H3K4me3) or acetylation of histone H3 at Lysine 27 (H3K27ac) associated with actively transcribed genes, whereas trimethylation of histone H3 at Lysine 27 (H3K27me3) is associated with repressed transcription [13] . To study chromatin accessibility, the assay for transposase-accessible chromatin with high-throughput sequencing (ATAC-seq) was developed. It is a powerful method for the simultaneous analysis of chromatin accessibility, nucleosome positioning and transcription factor occupancy [14] . Again, this method has been extended to the single-cell level [15] , and further refinements now allow the combination with visualization where the accessible genome can be imaged in situ ('ATAC-see') and the corresponding cells are accessible to cell sorting [16] . A summary of current approaches as applied to the epigenetic analysis of T cells is given in Table 1 . Evidently, all these approaches generate huge data sets, particularly when applied to complex research questions such as the differentiation of T cells from na€ ıve via effector to memory cells during an ongoing immune response. Therefore, appropriate bioinformatics resources are mandatory, and novel algorithms and platforms have been developed to integrate the analysis of multiple approaches [17, 18] . A schematic overview of the principles of epigenetic mechanisms of gene regulation is presented in Fig. 1 .
Epigenetics of T-cell specification
T cells are generated from haematopoietic stem cells and undergo T-cell receptor (TCR) repertoire development and fitness selection ('central tolerance') during intrathymic differentiation. The cell fate decision of haematopoietic stem cells and their differentiation into distinct cell lineages is governed by epigenetic processes including directional changes in DNA methylation [19] (see Fig. 2 for an overview). Recent studies have investigated the specification of T cells as compared to other leukocytes on a global (epi)genetic level. Lara-Astiaso and coworkers focused on the chromatin state dynamics in 16 welldefined cell populations during haematopoiesis spanning from multipotent progenitor stages to common lineage (myeloid, lymphoid) progenitors and terminally differentiated cells including CD4 and CD8 T cells. To achieve this with only a few cells, they developed an indexing-first ATAC-seq, assay for transposase-accessible chromatin with high-throughput sequencing; MNase-seq, micrococcal nuclease digestion combined with sequencing; DNase-seq, DNase I digestion combined with highthroughput sequencing; NOMe-seq, nucleosome occupancy and methylome sequencing; CapStarr-seq, self-transcribing active regulatory region sequencing using capture approach; ChIP-seq, chromatin immunoprecipitation assay with sequencing; WGBS, whole-genome bisulphite sequencing; MeDIP-seq, methylated DNA immunoprecipitation assay with sequencing; CMS-IP, cytosine-5-methylenesulphonate immunoprecipitation; GRO-seq, global run-on sequencing.
chromatin IP (iChIP) method where barcoding of the total cellular chromatin from sorted cell populations is performed, thus enabling multiple chromatin-barcoded samples to be pooled for ChIP in one well [20] . They profiled four histone marks in H3 to define promoter (high H3K4me3) and enhancer (high H3K4me1/2 and low H3K4me3) regions and enhancer activity by combined H3K27ac and RNA expression levels. Thereby, LaraAstiaso and coworkers confirmed previously described lineage-specific enhancers, but additionally identified a number of enhancers which are established de novo during haematopoiesis. This study revealed that lineage-specific enhancers are associated with transcription factor cohorts, confirming the notion that the transcription factors PU.1, GATA1 and Foxo1 are potential regulators of myeloid, erythroid and lymphoid enhancers, respectively [20] . Genome-wide methylation analyses performed by Zilbauer et al. in a small group of healthy individuals described cell type-specific hypomethylated regions correlating with gene transcription in CD4 and CD8 T cells in comparison with purified B cells, neutrophils and monocytes [21] . Focusing on the interindividual genomewide transcriptional and epigenetic specification of human immune cells in large cohorts of healthy individuals, two recent studies have further illustrated in detail how adaptive T cells segregate from innate monocytes and neutrophils [22, 23] . Not unexpectedly, characteristic epigenomic alterations have been attributed to the ageing process, for example large numbers of DMRs have been identified in CD4 T cells from three cohorts of newborns, middle-aged and longlived (centenarian) individuals which were correlated to transcriptional regulation [24, 25] . Genomewide methylation studies were also performed in CD4 T cell subsets which specifically differ between young and old individuals, for example based on CD28 expression. CD28 delivers an essential costimulatory signal during T-cell activation, and there is an age-dependent decline in CD28 expression as part of the immunosenescence process [26] . SuarezAlvarez and colleagues studied genome-wide DNA methylation and gene expression profiles of CD28-negative and CD28-positive CD4 T cells and identified hundreds of differentially methylated genes related to chemokine/ cytokine signalling, cytotoxic activity and TCR signalling, in line with pro-inflammatory features of CD28-negative CD4 T cells [27] . Other investigators characterized na€ ıve CD8 T cells from young and old individuals; the integrated analysis of ATAC-seq and RNA-seq data again helped to identify age-related transcription networks and revealed a loss of chromatin accessibility in aged CD8 T cells [28] . Another recent publication reported on the epigenetic landscape of human neonatal CD8 T cells in comparison with adult healthy donors. By combined ChIP-seq and RNA-seq, these authors found that neonate CD8 T cells are skewed towards innate immune responses with low cytotoxic potential [29] . Depending on the priming conditions, mature T cells can differentiate into functionally distinct subsets, notably Th1, Th2, Th17, Tfh and Treg, each associated with a characteristic transcription factor and cytokine profile [30] . Such transcription factor profiles include T-bet (Th1), GATA-3 (Th2), RORct (Th17), c-MAF (Tfh) and FoxP3 (Treg). However, a closer look indicates that the expression of a given transcription factor is not always restricted to a particular T-cell subset, that is promiscuous expression patterns are observed [31] . In fact, FoxP3 + Treg cells coexpressing RORct were found to exert enhanced suppressive activity both in vitro and in vivo in a model of intestinal inflammation when compared to their RORctnegative counterparts [32] . Additional studies also pointed to a cytokine environment-dependent role of transcription factors T-bet and GATA-3 in shaping the suppressive function of Treg cells [33] . Not surprisingly, the cytokine and TCR signal strength-dependent differentiation of T cells into functional subsets is regulated by epigenetic mechanisms. An interesting study by Wei et al. [34] nicely illustrated the role of histone modifications in T helper subset plasticity. Using high-throughput ChIP-seq, these authors found a set of genes, alternative transcripts and regulatory elements in a genomewide H3K4me3 and H3K27me3 map in murine na€ ıve, Th1, Th2, Th17, naturally occurring Treg (nTreg) and induced Treg (iTreg) cells. Of interest, they found repressive H3K27me3 marks on the IL-4 gene only in na€ ıve, Th1 and Th17 cells, but not in Treg cells, which accordingly might express the bona fide Th2 cytokine IL-4. Similar observations were made for the Foxp3 locus in Th17 cells. In all T-cell subtypes, most of the signal transducers and activators of transcription (STATs) were marked with H3K4me3 in the promoter region, but without H3K27me3. This, in the case of STAT5, specifically indicated the alternative expression of two isoforms of STAT5b, depending on the fate decision of lineage commitment [34] . Further studies profiled active and poised enhancers in primary human Th1 and Th2 T cells by focusing on the genome-wide distribution of H3K4me2 marks [35] . By comparing Th2 cells from healthy and asthmatic individuals, this approach revealed disease-specific enhancers in Th2 cells which were further linked to combined analysis of single nucleotide polymorphisms (SNPs), transcription factors, microRNAs and gene expression [35] . Alternatively, functional T-cell commitment can be studied based on the methylation status of signature transcription factor and cytokine loci. As an example, the promoter methylation at the IL-17A locus has been used to profile ex vivo isolated CD4 T cells in the inflamed joints of patients with rheumatoid arthritis [36] . It should be noted with caution, however, that the transient expression of given transcription factors and associated cytokines cannot clearly identify unambiguous T-cell subset specification. Epigenetic processes have a much more pronounced role in the molecular identification of a given cell. For instance, a well-investigated case is the correlation between DNA methylation status of FoxP3 and the suppressive activity of nTreg cells [37] . As originally reported by J. Huehn and coworkers, there is selective demethylation in an evolutionarily conserved element within the FoxP3 locus termed Treg-specific demethylated region (TSDR) in naturally occurring Treg (nTreg) but neither in induced Treg (iTreg) nor in activated conventional CD4 T cells (which transiently upregulate FoxP3 protein expression) [38, 39] . Continued demethylation at the TSDR is required to maintain the suppressive function of Treg. Interestingly, however, expression of FoxP3 and induction of epigenetic regulation including hypomethylation are two independent events triggered by TCR stimulation during intrathymic development of nTreg cells [40] . Recent data assign an important role to the genome organizer Satb1 in the epigenetic orchestration of intrathymic Treg development [41] . As reported by Kitagawa 
cd T cells versus ab T cells: what about epigenetics?
Based on TCR expression, two subpopulations of T cells can be differentiated, that is ab and cd T cells. ab T cells carry a CD3-associated abTCR which is generated from a large pool of available Va and Vb genes upon somatic TCR gene rearrangement during intrathymic T cell differentiation. In the periphery, most ab T cells are either CD4 or CD8 single positive. Mature CD4 and CD8 T cells recognize peptides presented by MHC class II or MHC class I molecules, respectively [43] . A separate lineage of T cells expresses the alternative cdTCR. The germlineencoded cdTCR repertoire is much smaller compared to ab T cells. Moreover, cd T cells recognize different ligands and without MHC restriction. The major population of cd T cells in human peripheral blood recognizes microbe-or tumour-derived pyrophosphates ('phosphoantigens') and therefore plays a role in anti-infective and tumour immunity [44] . Like their ab T cell counterpart, cd T cells display a wide functional plasticity spanning from distinct cytokine expression patterns to regulatory activity and even antigen-presenting capacity [45] . It can be anticipated that epigenetic regulation plays a major role also in controlling cd T cell functions (see Fig. 2 ). Thus, at least two events in intrathymic T cell development are controlled by epigenetic mechanisms, that is the transition from progenitor cells via different stages of CD4 -CD8 -double-negative (DN) to CD4 + CD8 + double-positive (DP) thymocytes and eventually mature CD4 + and CD8 + singlepositive (SP) T cells, and the acquisition of suitable ab or cd TCR. While the earliest phase is characterized by high transcriptional activity and gain of permissive H3K4me3 marks, repressive H3K27me3 marks characterize later stages from DN to DP transition, restricting the T-cell specification programme upon progressing differentiation [46] . The zinc finger transcription factor Th-POK was identified as the master regulator of CD4 T cell differentiation. In the DP stage, Th-POK is marked by both H3K4me3 and H3K27me3 and thus is in a bivalent state. This resolves into permissive H3K4me3-only state in CD4 T cells and repressive H3K27me3-only state in CD8 T cells, thus positioning the epigenetic control of Th-POK as a central regulator of CD4 versus CD8 T cell branching [47] . This process is further influenced epigenetically by additional transcription factors including Mazr and RUNX family members [48] . Furthermore, the genome organizer Satb1 was recently identified as an essential component in the activation of lineage-specifying transcription factors in the thymus. Satb1 regulates enhancers in these genes in a locus-specific manner and thus is required for appropriate T-cell lineage development [49] . Chromatin remodelling during cellular differentiation is a dynamic process. Comparing wild-type and Ets1-deficient thymocytes, Cauchy et al. reported that the ability of the transcription factor Ets1 to bind to nucleosomal DNA changes during differentiation, correlating with the expression of a specific transcriptional programme during the DN to DP transition [50] . Importantly, epigenetic regulation during T-cell lineage commitment is not limited to histone modification but similarly involves DNA modifications. DNA methyltransferases (DNMTs) mediate cytosine methylation (5mC), most notably in the CpG islands. In recent years, another DNA modification has been described, mediated by ten-eleven translocation (TET) proteins which catalyse the hydroxylation of 5mC to 5-hydroxymethylcytosine (5hmC) in DNA [51] . A genomewide mapping of 5hmC during sequential steps of thymocyte differentiation was performed by Tsagaratou et al. [52] . Based on cytosine-5-methylensulphonate (CMS) containing DNA immunoprecipitation (CMS-IP) followed by deep sequencing, these authors showed that 5hmC levels in the gene body strongly correlate with histone modifications and gene expression, and change dynamically during T-cell differentiation [52] .
Epigenetic regulation is also important for the process of TCR gene rearrangement. For successful V(D)J recombination to occur, the lymphoid-specific RAG1/2 recombinases need to have access to the respective loci, and transcriptional enhancers and promoters control this process via the modulation of the chromatin structure [53] . Moreover, it has been shown that high and extended H3K4me3 marks are present throughout the Db-Jb-Cb gene segments of the TCRB locus which depends on RNA polymerase IImediated transcriptional activity, which together with the extended H3K4 trimethylation renders Db and Jb gene segments highly accessible [54] . It is also important to note that specific TCRD gene rearrangements occur in a strict order which is dependent on RUNX proteins. Thus, it was recently shown that RUNX1 mediates the specific targeting of the RAG1 recombinase to the Dd2-23 recombination signal sequence, and inhibition of RUNX1 binding disrupted the order of TCR-d rearrangement in suitable in vitro differentiation models [55] .
Studies on the transcriptional and epigenetic profile of cd T cells are limited. Several groups have investigated the transcriptome of human peripheral blood cd T cells in comparison with ab T cells and NK cells, also with regard to modulation by selected costimuli such as Toll-like receptor ligands [56, 57] . Phosphoantigens such as isopentenyl pyrophosphate (IPP), generated through a dysregulated mevalonate pathway in tumour cells, or microbe-derived phosphoantigens and pathogen-associated molecule patterns from infectious pathogens are sensed by cd T cells as a 'danger signals'. Functional studies have also discovered differences in the priming requirements of cd T cells as compared to ab T cells with regard to induction of selected cytokines. We recently reported that potent IL-9 production is induced in human cd T cells by TCR activation in the presence of TGF-b, whereas the induction of IL-9 in ab T cells required IL-4 plus TGF-b [58] . Similarly, murine intraepithelial cd T cells have been extensively characterized at the transcriptional level [59] . In recent years, cd T cells have been also identified as an important source of early IL-17 production. In fact, IL-17-and interferon-c (IFN-c)-producing cd T cells have been characterized as distinct subsets which develop in the mouse thymus, correlating to some extent with CD27 surface expression. Schmolka et al. performed a genomewide histone (H3) acetylation and methylation profiling of murine IL-17-versus IFN-c-producing cd T cells. These studies showed that both subsets share an early developmental programme but acquire distinct molecular profiles during the functional polarization [60] . Overall, the available data support the notion that CD27 + murine cd T cells have a stable IFN-c-producing phenotype while the CD27 -counterpart displays more functional plasticity [61] . In humans, promiscuous IL-17 + /IFN-c + cd T cells have been identified under inflammatory conditions [62] . Taken together, it is now widely accepted to classify cd T cells as 'innate-like' T cells which can exert an immediate response upon sensing danger signals [44] .
We have recently set out to generate a detailed epigenetic landscape of human cd T cells in comparison with ab T cells. To this end, we compared purified cd T cells and ab T cell subsets (CD4, CD8, Treg) from healthy individuals at multiple regulatory levels of epigenetic processes. The combined analysis will allow us to identify important genes that are differentially regulated in cd and ab T cells (Bhat et al., unpublished) .
Generation of T-cell memory
Memory is the hallmark of adaptive immunity. During an ongoing immune response, a fraction of T cells differentiate into long-lived memory cells which persist in niches in the bone marrow, and can rapidly respond upon re-encounter of the specific antigen [63] . The differentiation of a T cell from the na€ ıve stage via the effector towards the memory stage is accompanied by the expression of sets of cell surface markers and specific transcriptional and epigenetic programmes [64] . Overall, generation of T-cell memory is linked to specific epigenetic events such as DNA methylation and repressive and permissive histone modifications [65] . On a genome-wide level, permissive (H3K4me3) and repressive (H3K27me) histone marks were found to correlate with gene expression in distinct subset of na€ ıve and memory CD8 T cells [66] . Further investigations have characterized the dynamics of permissive and repressive histone marks in ex vivo isolated na€ ıve, effector and memory CD8 T cells during an ongoing influenza virus infection. These studies revealed a focused reduction of repressive H3K27me marks in memory CD8 as compared to na€ ıve CD8 T cells [67] . Integrated systems biology approaches based on available GEO data sets have also been used to identify regulatory networks of transcription factors associated with CD8 T cell memory development. In addition to known transcription factors, these studies have helped to identify novel key factors for this process such as Bach2 [68] . A recent study by Yu et al. applying a multilayer epigenetic approach including RNA-seq, ChIP-seq and ATAC-seq to study gene expression, genome-wide histone modifications and chromatin accessibility additionally identified transcription factors with novel roles in CD8 T cell differentiation. Specifically, these authors found that the nuclear glucocorticoid receptor nuclear receptor subfamily 3 group C member 1 (Nr3c1) regulates memory precursor CD8 T cells during infection with the intracellular microbe Listeria monocytogenes [18] . In addition to histone modifications, acquired changes in DNA methylation characterize memory CD8 T cells. Using whole-genome sequencing of bisulphite-converted DNA, Abdelsamed and coworkers recently reported that human memory CD8 T cells maintain their subset-specific DNA methylation pattern upon cytokine-driven, antigen-independent in vitro proliferation and also upon adoptive transfer into transplant patients [69] .
Similar to CD8 T cells, epigenetic regulation also controls memory development in the CD4 T cell compartment. Kinkley and coworkers developed a modified ChIP-seq method which helped to identify bivalent HeK4me3 and H3K27me3 marks in human CD4 memory T cells [70] . A deep epigenomic profiling of human CD4 T cell subsets addressing DNA methylation, histone modifications, chromatin accessibility and coding and regulatory RNAs has defined specific characteristics of na€ ıve (T N ), central memory (T CM ), effector memory (T EM ) and terminally differentiated CD45RA + (T EMRA ) CD4 T cells [71] . These studies have not only defined critical factors controlling checkpoints for na€ ıve CD4 T cells (such as FOXP1) but also suggest a linear differentiation model of CD4 T cells during an ongoing immune response (T N ? T CM ? T EM ? T EMRA ) based on transcriptome analysis, chromatin accessibility and DNA methylation [71] . Importantly, epigenetic mechanisms also regulate the expression of homing receptors on CD4 memory T cells. As shown by Szilagyi et al., expression of the mucosaspecific homing receptor a 4 b 7 integrin on murine CD4 memory T cells is maintained also in the absence of inducing factors, due to selective DNA demethylation [72] .
As briefly discussed here, there is no doubt that epigenetic mechanisms are essential for memory T-cell responses and development. Despite enormous progress, however, many questions remain open at this point. As an example, the role of 'super-enhancers' in the maintenance of memory T cell function after cell division remains to be specified in more detail [73] .
Epigenetics of T cells in autoimmunity
Autoimmune diseases are characterized by inappropriate immune regulation, thus allowing autoreactive B and/or T cells to develop into effector cells. Not surprisingly, T cell function in autoimmune diseases like rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) or multiple sclerosis (MS) is also regulated by epigenetic mechanisms [74] . Given the exceptional role of Treg cells in controlling peripheral tolerance, altered epigenetic modification affecting FoxP3 (e.g. demethylation at the TSDR region) or other genes controlling Treg activity may contribute to the pathogenesis of autoimmune diseases [75] (see Fig. 3 ). MS is usually considered to be a CD4 T cell-mediated (or at least dependent) autoimmune disease. Sanders et al. recently compared miRNA profiles of CD4 T cells from patients with secondary progressive MS with healthy donors. Results obtained by NGS and validated by RTqPCR identified several miRNAs specifically downregulated in MS CD4 T cells, with the suppressor of cytokine signalling 6 (SOCS6) being one gene targeted by eight of ten of the identified miRNAs [76] . Moreover, genomewide DNA methylation studies have identified DMRs of CD4 T cells in MS patients compared to healthy controls, specifically on chromosome 6p21 at HLA-DRB1 (a known MS risk locus), and additional non-HLA CpGs that localized to 190 Epigenetics of T-Cell Differentiation genes linked with MS [77] . Interestingly, the methylation profile of CD8 T cells in the same cohort of patients with relapsing remitting MS differed from CD4 T cells, supporting the notion that it is important to consider cell type-specific epigenetic regulation [78] . Mouse models of MS illustrate how targeting epigenetic mechanisms can also contribute to the design of novel therapies. The hypomethylating agent decitabine was found to ameliorate clinical symptoms in experimental allergic encephalomyelitis (EAE), associated with increased production of antiinflammatory cytokines and induction of Treg cells [79] . On the other hand, DNA demethylation can also promote autoimmunity as shown in lupus-prone MRL/lpr mice by Wu and coworkers. These authors observed activation of follicular helper T cells (Tfh) together with enhanced lupus symptoms in these mice upon high sodium chloride diet. They found that Tfh polarization was due to DNA demethylation as a consequence of NaCl-induced recruitment of TET enzymes [80] . Widespread epigenetic alterations are also present in CD4 T cells from SLE patients compared to age-and sex-matched healthy controls. Thus, specific changes in DNA methylation correlating with clinical phenotypes were detected in novel key target genes including NLRP2, CD300LB and S1PR3 [81] . Moreover, CD4 T cells from SLE patients display upregulated expression of TET2/3 enzymes, and increased 5hmC levels were found in the promoter regions of many immunerelated genes, in agreement with upregulated gene expression [82] . It appears that disease-associated changes in the genome-wide DNA methylation pattern are present as well in other autoimmune diseases including RA [83, 84] , Grave's disease [85] or Behc ßet's disease [86] . In addition to T cells, such alterations can also extend to B cells [83, 84] or monocytes [86] . Overall, these few examples illustrate that epigenetic mechanisms are involved in many if not most autoimmune diseases but also offer novel targets for therapeutic intervention [87] . However, it should be kept in mind that the precise role of epigenetic processes in the pathogenesis is not known for most autoimmune diseases, in part due to relatively small patient cohorts.
Epigenetic drugs
The epigenetic code is executed by enzymes targeting histone modifications (such as histone deacetylases, HDAC; or histone acetyl transferases, HAT) and DNA methylation (such as DNA methyltransferases, DNMT; and TET enzymes). Corresponding inhibitors and activators interfere with epigenetic regulation and may have profound effects on T-cell differentiation and immune responses (see Figs 2  and 3 ). Demethylation at the TSDR region of FoxP3 is required for sustained Treg activity. In line, the DNMT inhibitor decitabine (5-aza-2 0 -deoxycytidine) was found to induce and stabilize FoxP3 expression and Treg activity in murine and human CD4 T cells [88, 89] . Interestingly, similar effects can be mediated by vitamin C (VC). VC does not only have strong antioxidant activity but also increases TET enzyme activity and thereby DNA hydroxymethylation. This results in FoxP3 demethylation and stabilization and thereby preserved Treg activity [90, 91] . Our own studies indicate that VC can enhance and stabilize the expression of FoxP3 and selected other transcription factors also in human peripheral blood cd T cells (Kouakanou et al., unpublished). In addition, it was recently observed that VC can also induce histone modifications. As reported by Song et al., VC enhanced the expression of IL-17 in murine CD4 T cells by modulating the histone deacetylase Jumonji C domain-containing protein 2 (Jmjd2), thereby reducing H3K9me3 marks in the IL-17 gene [92] .
Apart from DNMT inhibitors, several other substances are investigated in T-cell epigenetics. These include epigallocatechin gallate (EGCG), a polyphenol present in green tea [93, 94] , TET activator vitamin C, the natural product curcumin, a CBP/p300-specific HAT inhibitor, and the chemically synthesized HAT inhibitor CBP30. Curcumin and CBP are reported to induce anti-inflammatory response by inhibiting NFjB and AP-1 transcription factors. Curcumin inhibited release of chemokines like MIP-1a, MIP-1b and RANTES in human cd T cells [95] , while CBP30 inhibited IL-17A secretion by Th17 cells from healthy human individuals and patients with ankylosing spondylitis and psoriatic arthritis [96] .
The HDAC inhibitor valproic acid (VPA) is in clinical use for the treatment of epilepsy and bipolar disorders but is also widely used to interfere with epigenetic regulation. When comparing human peripheral blood ab and cd T cells, we observed substantial differences in the modulation of some surface markers by VPA. Cell surface antigens which were substantially more affected in cd T cells included CD86, CD54 and NKG2D [97] . We also found that VPA induced the expression of a non-secreted isoform of IL-4 (IL-4 d 13) in cd T cells which was linked to histone H3 acetylation and regulation of the c-Jun transcription factor network [98] . VPA as well as newly emerging other HDAC inhibitors and DNMT inhibitors have multiple direct effects on tumour cells, but accumulating evidence indicates that they may additionally modulate the antitumour immune response, for instance via the NKG2D receptor/ligand interaction. The activating NKG2D receptor is expressed on CD8 T cells, NK cells and cd T cells but rarely on CD4 T cells. In line, NKG2D is hypermethylated (i.e. silenced) in CD4 T cells whereas it is hypomethylated in CD8 T cells, which also correlates with the H3K9ac status [99] . NKG2D ligands including MICA/B and ULBP family members are not present on normal cells but are constitutively expressed on some but not all transformed cells where they serve as targets for recognition by NKG2D-expressing cytotoxic effector cells. MIC genes might be silenced through promoter hypoacetylation, as shown for Merkel cell carcinoma (MCC), in which Ó 2017 The Foundation for the Scandinavian Journal of Immunology case MICA/B expression and thus susceptibility to NKG2D-dependent cytotoxicity could be reinstalled by HDAC inhibitors like Vorinostat and Mithramycin A [100] . Not unexpectedly, HDAC inhibitors also enhance the expression of other cell surface (e.g. HLA class I and ICAM-1) and intracellular molecules (e.g. LMP2, calnexin, b2-microglobulin) in tumour cells important for recognition by T cells and thereby can enhance T-cell-mediated lysis of tumour cells [101] . In view of the diverse effects of HDAC inhibitors and other epigenetic modifiers, it is tempting to explore possible synergies with other wellestablished antitumour therapies. Along this line, it was recently shown that the HDAC inhibitor panobinostat enhances the tumoricidal effect of anti-HER2 antibody trastuzumab through direct effects on tumour cells but also via enhancing antibody-dependent cytotoxicity [102] . Moreover, checkpoint inhibitors such as anti-PD-1 antibody in combination with HDAC inhibitors are under intensive investigation in various preclinical studies and clinical trials [103] . As an example, several clinical studies are underway with anti-PD-1 antibodies pembrolizumab or nivolumab, or anti-PDL-1 antibody atezolizumab in combination with HDAC inhibitor entinostat and/or DNMT inhibitor azacytidine (NCT02437136; NCT02697630; NCT01928576; NCT02453620; NCT02708680; NCT019 28576; http://clinicaltrials.gov). In a mouse lung cancer model, Zheng et al. showed that the combination of romidepsin (a selective class I HDAC inhibitor) and anti-PD-1 treatment promotes a positive chemokine-IFN-c feedback loop through tumour cells and T-cell intermediaries [104] . Notably, the synergistic effect of both romidepsin and PD-1 blockade leads to enhanced T-cell infiltration of tumours and increased T-cell functionality. While HDAC inhibitors might thus have perspectives for the treatment of certain cancer types, more in-depth studies are required. Our own work showing enhanced shedding of NKG2D ligands from tumour cells in response to HDAC inhibitors (Bhat et al., submitted for publication) and other studies pointing to a dual role of HDAC in tumorigenesis according to the stage of tumour progression [105] raise a note of caution.
Future perspectives
As we have discussed here, epigenetic regulation is an essential component of T cell differentiation [106] . Technological progress has opened new possibilities to study epigenetic regulation even at the single-cell level, thereby paving the way for deeper insights into normal and pathological T cell differentiation. Thus, future studies will allow detailed investigations of single T cells at different localizations, for instance in inflamed tissues or in the tumour microenvironment. Another important development is the potential use of epigenetic modifiers to enhance immune responses in vivo [107] . Detailed studies are warranted to find out under which conditions HDAC inhibitors used in the clinic can enhance antitumour immune responses, also in the context of tumour vaccination. Similarly, modulators of DNA methylation and hydroxymethylation might offer interesting perspectives for clinical application. As an example, it has been demonstrated that decitabine can upregulate the expression of NKG2D ligands [108] . In addition, decitabine may support antitumour immune responses by mechanisms unrelated to epigenetic regulation, for example by depleting myeloid-derived suppressor cells [109] . Vitamin C has been shown to stabilize FoxP3 expression in Treg cells via TET proteins and thus may prove useful to enhance Treg activity in certain conditions such as autoimmune diseases. These few examples illustrate that we currently witness an exciting period where results of basic research in T-cell epigenetics help to shape novel therapeutic strategies.
